ArticleClinical kidney journal2025
Increased risk of cardiac death with cumulative exposure to fluid overload and dialysate sodium ≤138 mmol/l in hemodialysis patients.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of reduced ultrafiltration rate on the cardiac biomarkers NT-proBNP and troponin T: a prospective crossover study.BMC nephrology · 2026Article
- Epidemiology and Multimorbidity in Hemodialysis Patients at a Tertiary Care Center in Northern Mexico: Implications for Hospital-Based Adverse Outcomes.Kidney & blood pressure research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fluid overload (FO) is an established risk factor for mortality in hemodialysis patients, who face higher cardiovascular mortality risk than the general population. Despite the known impact of FO on cardiovascular outcomes, the effects of cumulative FO exposure, dialysate sodium ≤138 mmol/l, and specific cardiac deaths remain unclear. This study aimed to assess these relationships in a large cohort of hemodialysis patients. Methods: This historical cohort study included 68 196 hemodialysis patients from the NephroCare network with data from 2010 to 2019. Eligible patients had valid bioimpedance, plasma, and dialysate sodium measurements within 90 days of starting hemodialysis. FO was defined as >7% relative FO, as assessed by bioimpedance spectroscopy. Cause-specific Cox proportional hazards models were used to evaluate the impact of these exposures on different cardiac endpoints, including death from heart failure, sudden cardiac death, and fatal myocardial infarction. Results: In 68 196 patients, a total of 2 123 957 patient-months were analyzed. Compared to patients with no prior exposure (0 month cumulative past exposure time), increasing cumulative exposure to FO (measured in months) significantly increased the risk of death from heart failure [hazard ratio (HR) peaking at 4.4, 95%CI: 3.4-5.6], sudden cardiac death (HR peaking at 4.0, 95%CI: 3.1-5.2), and fatal myocardial infarction (HR peaking at 3.3, 95%CI: 2.5-4.4). Cumulative exposure (in month) to dialysate sodium ≤138 mmol/l was associated with an elevated risk of death from heart failure (HR peaking at 6.0, 95%CI: 1.9-18.3) and a moderate increase in sudden cardiac death (HR peaking at 2.7, 95%CI: 1.3-5.6). The risk of all-cause mortality was consistently higher in patients exposed to FO (HR peaking at 3.4, 95%CI: 3.1-3.8) and those exposed to dialysate sodium ≤138 mmol/l (HR peaking at 2.0, 95%CI: 1.3-3.1). Conclusion: Cumulative FO and dialysate sodium ≤138 mmol/l significantly increase cardiac death risk in hemodialysis patients, particularly from heart failure. Stringent fluid management and careful consideration of dialysate sodium prescription is crucial to reduce cardiovascular mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.